Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium.Oral Presentation of Interim Analysis of Randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. , Head-to-Head Phase II Study of ABRAXANE Versus Taxotere( )In First-line Metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. Breast Cancer Poster Presentations Highlight Treatment of Breast Cancer with ABRAXANE in Various Settings and Dose Regimens LOS ANGELES Los Angeles (lôs ăn`jələs, lŏs, ăn`jəlēz'), city (1990 pop. 3,485,398), seat of Los Angeles co., S Calif.; inc. 1850. -- Abraxis BioScience, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ABBI Advanced Breast Biopsy Instrument (ABBI) Uses a rotating circular knife and thin heated electrical wire to remove a large cylinder of abnormal breast tissue. Mentioned in: Fibrocystic Condition of the Breast ), an integrated, global biopharmaceutical company, announced today that one oral and five poster presentations of ABRAXANE([R]) for Injectable Suspension (paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); protein-bound particles for injectable suspension) (albumin bound) will be presented at the 29th Annual San Antonio Breast Cancer Symposium, December 14 - 17, 2006. The studies to be presented are intended to highlight the clinical benefits of ABRAXANE in the treatment of breast cancer. In the oral presentation, interim data will be discussed from a 300 patient, randomized, Phase II head-to-head trial of ABRAXANE versus Taxotere([R]) (docetaxel) in the first-line treatment of metastatic breast cancer. The Phase II ABRAXANE study [Abstract Number 46: A Randomized Phase 2 Trial of qW or q3W ABI-007 (ABX ABX Antibiotics ABX Airborne Express ABX Abstracting ABX Albury, New South Wales, Australia - Albury (Airport Code) ABX Automatic Branch Exchange ABx Non-Antibiotics ABX Asset Backed Securities Index ABX Acoustic Bass Extension ) vs. q3W Solvent-Based Docetaxel (TXT TXT Text TXT Text File (filename extension) TXT Textile TXT Teletext TXT Tecnologia per a Tothom TXT Textron Corporation (stock symbol) ) as First-line Therapy in Metastatic Breast Cancer (MBC (Multimedia Benchmark Committee) A graphics benchmark that provides MPEG-2 and other tests. See GPC. )] was designed to examine first-line treatment with various doses of ABRAXANE given weekly and every three weeks compared to Taxotere dosed every three weeks in patients with metastatic breast cancer. In the trial, first-line treatment with weekly ABRAXANE compared to every three week ABRAXANE was also studied. The primary endpoints of the study are comparative toxicity and anti-tumor response, with a secondary endpoint of progression-free survival. The interim results will be presented orally on December 17, 2006 at 10:45 a.m. CST CST abbr. 1. Central Standard Time 2. convulsive shock treatment CST Central Standard Time Noun 1. in Ballroom B by William Gradishar, M.D. of Northwestern University, the lead investigator on the study. Additional ABRAXANE([R]) Posters Presentations December 14, 2006, 5:00 p.m.-7:00 p.m., Treatment: Chemotherapy - New Drugs and Formulations (Session 1) Synergistic effect of albumin-bound paclitaxel (Abraxane) and Anti-VEGF-a antibody (Avastin) on growth of orthotopic MDA-MB-231 breast tumors as well as lymphatic and pulmonary metastases (Poster Number: 1094) December 14, 2006, Treatment: Chemotherapy - New Drugs and Formulations (Session 1), 5:00 p.m.-7:00 p.m. Phase II trial of nanoparticle albumin-bound paclitaxel (ABX) + capecitabine (Xel) as first line treatment of metastatic breast cancer (MBC): interim results (Poster Number: 1096) December 15, 2006, Treatment: Neoadjuvant Therapy (Session 3), 5:00 p.m.-7:00 p.m. Neoadjuvant chemotherapy with sequential weekly nanoparticle albumin-bound paclitaxel (ABI-007, Abraxane(R)) followed by 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in locally advanced breast cancer (LABC): a phase II trial of the NSABP Foundation Research Group (Poster Number: 3068) December 15, 2006, Treatment: Neoadjuvant Therapy (Session 3), 5:00 p.m.-7:00 p.m. Preliminary results from a multicenter phase II trial of biweekly neoadjuvant gemcitabine, epirubicin, ABI-007 (GEA) with correlative SPARC tumor analysis (Poster Number: 3069) December 15, 2006, Treatment: Chemotherapy - General (Session 6), 5:00 p.m.-7:00 p.m. Single agent Abraxane given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network Study, #I-04-012) (Poster Number: 6073) About Breast Cancer According to the American Cancer Society American Cancer Society, n.pr established in 1913, this national volunteer-based health organization is committed to the elimination of cancer through prevention and treatment and to diminishing cancer suffering through advocacy, scholarship, research, , breast cancer is the most common cancer among women, other than skin cancer, and is the second leading cause of cancer death in women in the United States. The risk of having breast cancer for a woman sometime during her life is about one in eight. In 2006 alone, an estimated 213,000 new cases of breast cancer are expected to occur in women, and an estimated 41,000 women are expected to die from the disease. About ABRAXANE([R]) The U.S. Food and Drug Administration approved ABRAXANE([R]) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy Adjuvant chemotherapy Treatment of the tumor with drugs after surgery to kill as many of the remaining cancer cells as possible. Mentioned in: Neuroblastoma . Prior therapy should have included an anthracycline unless clinically contraindicated. For the full prescribing information for ABRAXANE([R]) please visit www.abraxane.com. ABRAXANE was developed by Abraxis BioScience, Inc. ABRAXANE is marketed in the United States under a co-promotion agreement between Abraxis BioScience, Inc. and AstraZeneca Pharmaceuticals LP. About Abraxis BioScience, Inc. Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab[TM] platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved product to use this nab platform, ABRAXANE([R]), was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the NASDAQ Stock Market Nasdaq stock market The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies. under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com. Taxotere([R]) is a registered trademark of Sanofi Aventis. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion